Revers profit warning with upgraded guidance for FY 2023.
Redeye is neutral in its assessment of Catella’s decision to divest its Infrahubs assets.
Omsättningen överstiger förväntningarna drivet av hög förvärvsaktivitet.
Redeye updates its estimates and fair value range after Ependion’s Q2 2023 report, which came in clo...
Norden och Nordamerika starka regioner i Q2 Beijer Almas omsättning växte organiskt med 3% i det and...
Omsättningen kom in över Analysguidens förväntan men vinsten är fortsatt under press.
Finnair should still have scope for further improvement, however current market conditions also info...
Redeye provides an initial take on Sedana Medical’s Q2 results, and we will return with updated esti...
Redeye updates its estimates and base case after reviewing Tessin's Q2 report, which showed sales ro...
Redeye states that Truecaller's Q2 report was strong in all aspects.
Redeye states that while Acconeer showed poor sales figures in Q2, the weakness is temporary.
Redeye retains its positive view of Sdiptech following a Q2 report that exceeded our expectations.
• Significant est. revisions from higher interest rates • Second credit rating downgrade has no impa...
• 27% org growth, 14% EBIT beat on strong AM sales • 26% adj.
• Another good quarter, 15% org. growth and 7.1% EBITA margin • Order intake still high, up 9% despi...
Consti’s Q2 report provided no real surprises, and the figures were largely in line with our estimat...
ADDvise, som förvärvar bolag inom hälso- och sjukvård bjöd på kraftigt förbättrad lönsamhet och fort...
• Q2 order beat but sales miss & FX make us cut EBIT -5% • Momentum is good and positive guidance wa...
Värdenedskrivningar drivet av senaste strukturaffärer ALM Equity avslutade ett intensivt första halv...
Starkt genom hela rapporten Bolaget följer upp rekordsiffrorna i Q1 med en ännu starkare rapport.
